In our study, tumors of the low-risk group showed a higher imputed sensitivity to a modulator (tamoxifen) and a degrader (fulvestrant) of ERα in two independent HNSCC cohorts, and in the combined cohort of nine other solid tumors from TCGA. The gene discussed is ESR1; the disease is head and neck squamous cell carcinoma.